PharmaBlock Sciences (Nanjing), Inc.

SZSE:300725 Stock Report

Market Cap: CN¥6.9b

PharmaBlock Sciences (Nanjing) Past Earnings Performance

Past criteria checks 1/6

PharmaBlock Sciences (Nanjing) has been growing earnings at an average annual rate of 6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 20.7% per year. PharmaBlock Sciences (Nanjing)'s return on equity is 6.4%, and it has net margins of 11.2%.

Key information

6.0%

Earnings growth rate

4.7%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate20.7%
Return on equity6.4%
Net Margin11.2%
Next Earnings Update30 Oct 2024

Recent past performance updates

PharmaBlock Sciences (Nanjing)'s (SZSE:300725) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Aug 23
PharmaBlock Sciences (Nanjing)'s (SZSE:300725) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Recent updates

PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) P/E Is Still On The Mark Following 40% Share Price Bounce

Sep 30
PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) P/E Is Still On The Mark Following 40% Share Price Bounce

PharmaBlock Sciences (Nanjing)'s (SZSE:300725) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Aug 23
PharmaBlock Sciences (Nanjing)'s (SZSE:300725) Sluggish Earnings Might Be Just The Beginning Of Its Problems

We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt

Jul 31
We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt

PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Increasing Its Dividend To CN¥0.31

Jun 12
PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Increasing Its Dividend To CN¥0.31

PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Apr 21
PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 25% Price Jump

Mar 07
PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 25% Price Jump

Revenue & Expenses Breakdown

How PharmaBlock Sciences (Nanjing) makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300725 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,626182252140
31 Mar 241,719189259155
31 Dec 231,725197263169
30 Sep 231,701219266180
30 Jun 231,704275271189
31 Mar 231,642301268189
01 Jan 231,595314256168
30 Sep 221,483294240154
30 Jun 221,315258211135
31 Mar 221,251488184112
31 Dec 211,202487177114
30 Sep 211,200484171115
30 Jun 211,184478161103
31 Mar 211,137226167103
31 Dec 201,02218415791
30 Sep 2092317714477
30 Jun 2083117013078
31 Mar 2068114711172
31 Dec 1966215210069
30 Sep 196031578766
30 Jun 195581498756
31 Mar 195311477950
31 Dec 184781337944
30 Sep 184171097537
30 Jun 18362896143
31 Mar 18319756534
31 Dec 17273676225
30 Sep 17244626617
30 Jun 1721944880
31 Mar 1719637850
31 Dec 1618836820
30 Sep 1618330810
30 Jun 1617731540
31 Mar 1615625470
31 Dec 1513620590
31 Dec 147722250
31 Dec 135918190

Quality Earnings: 300725 has a large one-off gain of CN¥73.7M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: 300725's current net profit margins (11.2%) are lower than last year (16.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300725's earnings have grown by 6% per year over the past 5 years.

Accelerating Growth: 300725's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300725 had negative earnings growth (-33.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.6%).


Return on Equity

High ROE: 300725's Return on Equity (6.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies